After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
ATAI Life Sciences N.V. is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. The current market capitalization of ATAI Life Sciences N.V. is $317.12M. A total of 1.02 million shares were traded on the day, compared to an average of 1.63M shares.
In the most recent transaction, Rao Srinivas sold 61,640 shares of ATAI for 1.85 per share on Apr 02 ’24. After the transaction, the insider now owns 113,360 company shares. In a previous transaction on Apr 02 ’24, Kirpekar Sahil sold 35,801 shares at 1.85 per share. ATAI shares that Chief Business Officer owns now total 64,199.
Among the insiders who sold shares, Johnson Anne Nagengast disposed of 27,410 shares on Apr 02 ’24 at a per-share price of $1.85. This resulted in the Chief Financial Officer holding 73,590 shares of ATAI after the transaction. In another insider transaction, Brand Florian bought 20,000 shares at $1.16 per share on Nov 16 ’23. Company shares held by the insider now total 130,000.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. In terms of 52-week highs and lows, ATAI has a high of $2.85 and a low of $1.02.
As of this writing, ATAI has an earnings estimate of $BioXcel Therapeutics, Inc. per share for the current quarter. EPS was calculated based on a consensus of ATAI Life Sciences N.V. estimates, with a high estimate of $RTAI per share and a lower estimate of $ATI Inc..
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. ATAI’s latest balance sheet shows that the firm has $362.27M in Cash & Short Term Investments as of fiscal 2021. There were $743.00k in debt and $20.93M in liabilities at the time. Its Book Value Per Share was $1.46, while its Total Shareholder’s Equity was $385.96M.
Analysts Opinion
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ATAI is Buy with a score of 5.00.
